Special Issue "The Future of Influenza Virus Vaccines—Perspectives from the young investigators' point of view"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (28 February 2018).
Interests: influenza virus; influenza virus vaccines; hantavirus glycoprotein-antibody interactions; arenavirus glycoproein-antibody interactions; humoral immunity to flaviviruses
Current influenza virus vaccines have many shortfalls. Next-generation vaccines that offer longer lasting, broader and perhaps universal protection against influenza A and B viruses are urgently needed. Recent efforts aim at creating better vaccines that meet these criteria and several candidates are under development. However, there are still severe gaps in our understanding of (vaccine induced) immunity against influenza viruses and filling these gaps is critical on the path forward to better vaccines.
This special issue of Vaccines will give the next generation of influenza virologists (less than 10 years into their first tenure-track appointment) the opportunity to present their view on current gaps, new developments and the future of influenza virus vaccines and vaccine development. Importantly, this special issue aims to gather a wide range of perspectives on influenza virus vaccines ranging from specialists in influenza virus immunology, vaccinology, virus engineering, structural biology, host-pathogen interactions, transmission, surveillance and virus evolution to epidemiology and others.
Dr. Florian Krammer, PhD
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- influenza virus vaccines
- heterosubtypic immunity
- vaccine design
- antigen design
- influenza virus immunity